Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2026-04-08 @ 5:00 PM
Study NCT ID:
NCT02015520
Status:
COMPLETED
Last Update Posted:
2021-05-12
First Post:
2013-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
Sponsor:
CSL Behring
Organization:
Study Overview
Official Title:
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to identify an appropriate dose of study medication.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2013-003780-65 | EUDRACT_NUMBER | None | View |